From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development

Microbes Infect. 2020 Jul-Aug;22(6-7):245-253. doi: 10.1016/j.micinf.2020.05.004. Epub 2020 May 11.

Abstract

The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics.

Keywords: 2019-nCoV; Cross-protection; HCoV-19; SARS-CoV; SARS-CoV-2; Vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Betacoronavirus / genetics
  • COVID-19
  • COVID-19 Vaccines
  • Coronavirus Infections / classification
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Cross Protection
  • Humans
  • Pandemics / prevention & control*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control*
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / immunology
  • Severe Acute Respiratory Syndrome / prevention & control*
  • Vaccines, Inactivated / immunology
  • Viral Vaccines / classification
  • Viral Vaccines / immunology*

Substances

  • COVID-19 Vaccines
  • Vaccines, Inactivated
  • Viral Vaccines